Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lack of in vitro antimicrosporidian activity of thalidomide.

Literature DB >> 10471585

Lack of in vitro antimicrosporidian activity of thalidomide.

Abstract

Thalidomide was evaluated for its in vitro activity against Encephalitozoon species by using the MRC-5 cell system. A cytotoxic effect was observed for concentrations of 10(1) microg/ml (P < 10(5)) and 5 microg/ml (P < 10(5)). Thalidomide did not significantly inhibit the growth of any of the microsporidia under study. These data suggest that thalidomide is not an etiologic treatment in microsporidial enteritis.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1999 PMID： 10471585 PMCID： PMC89467

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

21 in total

1. The treatment of microsporidial diarrhoea with thalidomide.

Authors: D Sharpstone; A Rowbottom; M Nelson; B Gazzard
Journal: AIDS Date: 1995-06 Impact factor: 4.177

2. Immunologically confirmed disseminated, asymptomatic Encephalitozoon cuniculi infection of the gastrointestinal tract in a patient with AIDS.

Authors: C Franzen; D A Schwartz; G S Visvesvara; A Müller; A Schwenk; B Salzberger; G Fätkenheuer; P Hartmann; G Mahrle; V Diehl
Journal: Clin Infect Dis Date: 1995-12 Impact factor: 9.079

3. Cryptosporidium, enterocytozoon, and cyclospora infections in pediatric and adult patients with diarrhea in Tanzania.

Authors: J P Cegielski; Y R Ortega; S McKee; J F Madden; L Gaido; D A Schwartz; K Manji; A F Jorgensen; S E Miller; U P Pulipaka; A E Msengi; D H Mwakyusa; C R Sterling; L B Reller
Journal: Clin Infect Dis Date: 1999-02 Impact factor: 9.079

4. Enterocytozoon bieneusi as a cause of chronic diarrhea in a heart-lung transplant recipient who was seronegative for human immunodeficiency virus.

Authors: M Rabodonirina; M Bertocchi; I Desportes-Livage; L Cotte; H Levrey; M A Piens; G Monneret; M Celard; J F Mornex; M Mojon
Journal: Clin Infect Dis Date: 1996-07 Impact factor: 9.079

5. Thalidomide for the treatment of chronic graft-versus-host disease.

Authors: G B Vogelsang; E R Farmer; A D Hess; V Altamonte; W E Beschorner; D A Jabs; R L Corio; L S Levin; O M Colvin; J R Wingard
Journal: N Engl J Med Date: 1992-04-16 Impact factor: 91.245

6. Faecal tumour necrosis factor-alpha in individuals with HIV-related diarrhoea.

Authors: D R Sharpstone; A W Rowbottom; M R Nelson; M W Lepper; B G Gazzard
Journal: AIDS Date: 1996-08 Impact factor: 4.177

7. In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.

Authors: B Beauvais; C Sarfati; S Challier; F Derouin
Journal: Antimicrob Agents Chemother Date: 1994-10 Impact factor: 5.191

Review 8. Human microsporidial infections.

Authors: R Weber; R T Bryan; D A Schwartz; R L Owen
Journal: Clin Microbiol Rev Date: 1994-10 Impact factor: 26.132

9. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy.

Authors: J M Molina; E Oksenhendler; B Beauvais; C Sarfati; A Jaccard; F Derouin; J Modaï
Journal: J Infect Dis Date: 1995-01 Impact factor: 5.226

10. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy.

Authors: E J Shannon; R O Miranda; M J Morales; R C Hastings
Journal: Scand J Immunol Date: 1981 Impact factor: 3.487

1 in total

1. Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.

Authors: A Tadesse; E J Shannon
Journal: Clin Diagn Lab Immunol Date: 2005-01

1 in total